Abstract
Background/purpose: Excess weight has been identified as a potential risk factor for the development of post-COVID-19 condition (PCC). This review investigates whether excess weight increases the risk of neurological and neuropsychiatric symptoms associated with PCC. Methods: Studies published up to July 2023 were searched independently across eight electronic databases to evaluate the risk of developing neurological and neuropsychiatric symptoms more than 12 weeks post-infection between exposure and controls groups (excess weight vs. normal weight; obesity vs. non-obesity). Meta-analyses were conducted under a random-effects model. Results: Of the 10,122 abstracts screened, 18 studies (n = 139,091 adults) met the inclusion criteria and reported PCC symptoms according to nutritional status. These studies included 79,050 individuals with excess weight vs 57,926 normal-weight individuals and 30,694 individuals with obesity vs 107,612 non-obese individuals. The presence of excess weight in PCC significantly increased the risk of depression (RR = 1.21; 95% CI: 1.03–1.42), headache (RR = 1.21; 95% CI: 1.09–1.35), memory issues (RR = 1.43; 95% CI: 1.24–1.65), sleep disturbance (RR = 1.31; 95% CI: 1.16–1.48), and vertigo (RR = 1.21; 95% CI: 1.04– 1.41). Obesity significantly increased the risk of headache (RR = 1.41; 95% CI: 1.34– 1.49), smell disorder (RR = 1.15; 95% CI: 1.09–1.21), taste disorder (RR = 1.21; 95% CI: 1.07–1.36), and vertigo (RR = 1.44; 95% CI: 1.35–1.53). Conclusions: Excess weight or obesity increases the risk of experiencing neuro-symptoms related to PCC. Individuals with these conditions urgently need enhanced personalized care management in current post-pandemic context.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study does not require an ethics statemen
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
